

Summary: A 16-week, multi-center, open-label study evaluating the safety, tolerability, and efficacy of switching from quetiapine to an investigational drug in subjects diagnosed with schizophrenia or schizoaffective disorder.

Inclusion:

- 18-55 years
- Male or female (females must not be pregnant or become pregnant)
- Diagnosis of Schizophrenia, and subtype, or schizoaffective disorder.
- Must be capable of reading above a 6th grade level.

Exclusion:

- Any other Axis I disorder
- Subjects receiving less the 150mg of quetiapine a day for 3 months.
- History of Chronic Hepatitis.

Contact: Mindy Boos, LPN, Clinical Research Coordinator

Telephone: 785-270-4622

Email: miboos@stormontvail.org